Junction: Pulmonary Arterial Hypertension

Centrilobular Ground-Glass Opacities Can Add Significant Prognostic Value in IPAH

The presence of centrilobular ground-glass opacities (cGGO) on high resolution computed tomography (HRCT) adds prognostic value for patients with idiopathic pulmonary arterial hypertension (IPAH), according to a new study published in Respiratory Research. The results showed that patients with cGGO had the shortest liver transplant (LTx)-free survival time compared to patients with panlobular ground-glass opacities…

Macitentan Demonstrates Clinical Improvements in Patients With PAH

Treatment with macitentan improved right ventricular (RV) function and structure as well as cardiopulmonary hemodynamics in patients with pulmonary arterial hypertension (PAH). These were the main conclusions of the Right vEntricular remodeling in Pulmonary ArterIal hypeRtension (REPAIR) study, recently published in the Journal of the American College of Cardiology (JACC): Cardiovascular Imaging. “At a prespecified…

Early Immunosuppressive Therapy May Be Successful for Patients With PAH

Researchers from Japan showed that immunosuppressive therapy can be successful for patients with pulmonary arterial hypertension (PAH) due to Takayasu arteritis, according to a new study published in Internal Medicine. They concluded that, when the disease is diagnosed in its early stage, the treatment can be successful without the need for endovascular or surgical procedures.…

CTRP9 Could Affect Pulmonary Arterial Hypertension Pathogenesis

Researchers investigated the molecular mechanisms of C1q/TNF-related protein 9 (CTRP9) in the context of pulmonary arterial hypertension (PAH) and discovered some previously unrecognized effects that it exerts on pulmonary vascular homeostasis during PAH pathogenesis. Their findings were published in Cardiovascular Therapeutics. Studies show PAH causes increased pulmonary vascular resistance, right heart failure, and premature death.…

MicroRNA miR-1226-3p Has Protective Effects in PAH Disease Models

Jian and Xia discovered that the microRNA miR-1226-3p promoted the endothelial nitric oxide synthase (eNOS) expression of pulmonary arterial endothelial cells and protected rat models from injury caused by pulmonary arterial hypertension (PAH), according to a new study published in BioMed Research International. Scientists have observed pathological changes in patients with PAH, such as pulmonary…

Activity Trackers Can Yield Discordant Results for Patients With PAH

Two different activity trackers for tracking physical activity in patients with pulmonary arterial hypertension (PAH) yielded discordant results, according to a new study published in European Heart Journal. “Activity trackers for clinical trials and remote monitoring are appealing as they provide objective data outside of the clinic setting,” Lachant et al wrote. In addition, scientists…

Inhibiting NLPR3 Inflammasome Pathway Could Attenuate Cardiac Failure in PAH

Chinese researchers have discovered that selective inhibition of the NLPR3 inflammasome contributes to the attenuation of lipopolysaccharide (LPS)-induced right ventricular failure (RVF) in rats with pulmonary arterial hypertension (PAH), according to a study published in the Journal of Inflammation Research. “RVF is the most important prognostic factor for both morbidity and mortality in patients with…

Sildenafil and Beraprost Combination Can Increase Quality of Life in PAH Patients

Indonesian researchers have discovered that a combination of sildenafil and beraprost significantly increased the health-related quality of life (HRQoL) of patients with pulmonary arterial hypertension (PAH) and uncorrected secundum atrial septal defect (ASD), compared to sildenafil alone, according to a study published in the Heart Science Journal. One of the causes of PAH is a…

Next post in PAH News Briefs